21 March 2025 false No description of principal activity Taxfiler 2024.6 16332609 business:PrivateLimitedCompanyLtd 2025-03-21 2026-03-31 16332609 2025-03-20 16332609 2025-03-21 2026-03-31 16332609 business:AuditExempt-NoAccountantsReport 2025-03-21 2026-03-31 16332609 business:FilletedAccounts 2025-03-21 2026-03-31 16332609 2026-03-31 16332609 business:Director1 2025-03-21 2026-03-31 16332609 business:RegisteredOffice 2025-03-21 2026-03-31 16332609 core:WithinOneYear 2026-03-31 16332609 core:ShareCapital core:PreviouslyStatedAmount 2026-03-31 16332609 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2026-03-31 16332609 core:PreviouslyStatedAmount 2026-03-31 16332609 business:SmallEntities 2025-03-21 2026-03-31 16332609 countries:EnglandWales 2025-03-21 2026-03-31 16332609 business:OrdinaryShareClass1 2025-03-21 2026-03-31 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. 16332609 (England and Wales)
Blood Scaffolding Ltd Unaudited accounts for the period from 21 March 2025 to 31 March 2026
Blood Scaffolding Ltd Company Information for the period from 21 March 2025 to 31 March 2026
Director
Nathaniel Aaron BLOOD
Company Number
16332609 (England and Wales)
Registered Office
Flat 18 Northwood House 15-17 Warminster Road London London SE25 4DP England
- 2 -
Blood Scaffolding Ltd Statement of financial position as at 31 March 2026
2026
Notes
£
Current assets
Cash at bank and in hand
34,750
Creditors: amounts falling due within one year
4
(33,599)
Net current assets
1,151
Net assets
1,151
Capital and reserves
Called up share capital
5
100
Profit and loss account
1,051
Shareholders' funds
1,151
For the period ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 8 June 2026 and were signed on its behalf by
Nathaniel Aaron BLOOD Director Company Registration No. 16332609
- 3 -
Blood Scaffolding Ltd Notes to the Accounts for the period from 21 March 2025 to 31 March 2026
1
Statutory information
Blood Scaffolding Ltd is a private company, limited by shares, registered in England and Wales, registration number 16332609. The registered office is Flat 18, Northwood House, 15-17 Warminster Road, London, London, SE25 4DP, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
4
Creditors: amounts falling due within one year
2026
£
Taxes and social security
246
Loans from directors
33,353
33,599
5
Share capital
2026
£
Allotted, called up and fully paid:
100 Ordinary shares of £1 each
100
6
Average number of employees
During the period the average number of employees was 1.
- 4 -